NAGIOS: RODERIC FUNCIONANDO

Salivary gland application of botulinum toxin for the treatment of sialorrhea

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Salivary gland application of botulinum toxin for the treatment of sialorrhea

Mostra el registre parcial de l'element

dc.contributor.author Fuster Torres, Mª Ángeles es
dc.contributor.author Berini Aytés, Leonardo es
dc.contributor.author Gay Escoda, Cosme es
dc.date.accessioned 2017-11-20T08:45:40Z
dc.date.available 2017-11-20T08:45:40Z
dc.date.issued 2007 es
dc.identifier.citation Fuster Torres, Mª Ángeles ; Berini Aytés, Leonardo ; Gay Escoda, Cosme. Salivary gland application of botulinum toxin for the treatment of sialorrhea. En: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, 12 7 2007: 8- es
dc.identifier.uri http://hdl.handle.net/10550/63139
dc.description.abstract Sialorrhea or excessive salivation, and drooling, are common and disabling manifestations in different neurological disorders. A review is made of the literature, based on a PubMed search, selecting those articles describing clinical trials involving the injection of botulinum toxin A in the salivary glands of patients with different diseases characterized by sialorrhea. The most frequently treated diseases were infant cerebral palsy (30%), Parkinson?s disease (20%) and amyotrophic lateral sclerosis (15%). Over half of the authors injected the product into the parotid glands, 9.5% into the submaxillary glands, and 38% into both. The total doses of toxin injected varied from 10-100 units of Botox® or 30-450 units of Dysport® according to the different authors. A reduction was observed in the production of saliva following these injections, and the duration of the therapeutic effect was 1.5-6 months. Six articles (30%) described the presence of adverse effects such as dysphagia, xerostomia and chewing difficulties. Most of the clinical studies involved small patient samples, with no blinding or randomization, and no control group. Moreover, no data are available on the efficacy and adverse effects of treatment in the context of long-term prospective studies. The effective therapeutic dose and ideal form of application remain to be established, and require the conduction of further controlled clinical trials involving large sample sizes. es
dc.title Salivary gland application of botulinum toxin for the treatment of sialorrhea es
dc.type journal article es_ES
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.identifier.doi es
dc.type.hasVersion VoR es_ES

Visualització       (134.0Kb)

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques